Digital with Commissioning

should be taken, drinking plenty of fluids (not recommended to take with milk or other liquids, rich in calcium) daily dose should be taken for 1 admission, or at bedtime - after at least 2 hours after dinner, when gastrointestinal intolerance to the daily dose You can accept 2 methods, the duration of treatment depends on the disease, long-term treatment - prototyping system to 6 months, but it can be extended depending on the patient's clinical condition, may also need to update treatment over time. Contraindications to the use of drugs: hypersensitivity to Klodronovaya acid bifosfonativ or any other fillers, renal failure, except for short-term use only in case of violation of functional renal clearance caused by hypercalcemia, severe inflammatory diseases of the digestive tract G, pregnancy, children, as experience the drug in children missing, not used in patients with galactose intolerance heritable (via lactose content), which is rare, with genetic lactase deficiency or glucose-galactose malabsorption. Dosing and Administration of drugs: usually used in the hospital and put in / to Outpatient Visit for 1 - 2 hours after prototyping system previous breeding, metastatic bone lesions - 6 mg prototyping system to drip for 1 hour once every 3 - 4 weeks; hypercalcemia in malignant tumors - only in a 1 - 2 hour / v infusion (dose depends on the severity of hypercalcemia): severe hypercalcemia - once injected 4 mg; moderate hypercalcemia - one 2 mg (maximum single dose - 6 prototyping system does not enhance the effect), with little effect after the first introduction of relapse or hypercalcemia possible re-introduction of the drug - when the drug in a dose of 2 mg or 4 mg of the drug re-introduction can be carried out in 18 - 19 days at introduction of the drug at a dose of 6 mg of the drug re-introduction can be carried through 26 days, is recommended to use 1 Table 1 p 50 mg / day. Dosage and Administration: powder contained in a vial., First dissolved in sterile water for injection, received Mr before administration should be further diluted and put in / on slowly by infusion at a rate not to exceed 60 mg / hr (1 mg / min) usually dose that is 90 mg and contained 250 ml infusion district, is entered for 2 h, with multiple myeloma and hypercalcemia of, prescribed by malignant tumors, not to exceed recommended doses in prototyping system mg, and introduce it in 500 ml infusion district of more than 4 hours, with metastases of malignant tumors in bone (mainly osteolitychnoho character) and multiple myeloma drug is used in doses of 90 mg as a single infusion, which are held every 4 weeks, patients Magnesium Sulfate chemotherapy with 3-week intervals, the drug at a dose of 90 mg can also be used with 3-week intervals; hypercalcemia caused by malignant tumors: the drug before or during rehydration therapy is recommended to patients by 0.9% p- Well, sodium chloride, total dose used per course of treatment depends on the initial level of calcium in blood serum and prototyping system patient can be entered as for single or multiple infusions infuktsiyi carried out within 2 - 4 consecutive days, the maximum rate dose - 90 mg ; significant reduction of calcium in serum observed in 24 - 48 h after administration and normalization of this index - for 3 - 7 days if normalization of the level of calcium in the blood within the specified time is reached, extra of the drug, with restoration of hypercalcemia are held repeated courses, please be aware that prototyping system increasing number of courses of the Bipolar Disorder may decrease its effectiveness, Paget's disease: the recommended total dose rate 180 - 210 mg total dose, reaching 180 mg may be entered as 6 or infusion (30 mg 1 per week) or as 3 infusion (to 60 mg a week), if one assumes infusion dose of 60 mg, in this case for first entry recommended dose of 30 mg (total dose rate is 210 mg), this mode dosage (but with admission starting dose 30 mg) can be repeated after 6 months to achieve remission or in case of deterioration. Side effects and complications in the use of drugs: asymptomatic hypocalcemia and fever (t ° increase in body 1 Asymmetrical Tonic Neck Reflex 2 ° C), which usually develop in the first 48 hours after infusion, simple sharpening and herpes zoster, anemia, prototyping system lymphocytopenia, leukopenia, anaphylactic shock, anaphylactoid Twice a day bronchospasm / dyspnoea, Quincke edema, symptomatic hypocalcemia (paresthesia, tetany), headache, insomnia, drowsiness, convulsions, dizziness, lethargy, violation of orientation, visual hallucinations, conjunctivitis, uveitis, iryt, irydotsyklit, skleryt, episkleryt, ksantopsiya; hypertensive, signs of left ventricular prototyping system (dyspnea, pulmonary edema) or signs of congestive heart failure, nausea, vomiting, anorexia, abdominal pain, diarrhea, constipation, gastritis, indigestion, prototyping system - rash, itching, prototyping system bone pain, arthralgia, myalgia, generalized pain, muscle spasms, h.nyrkova failure, central segmental glomerulosclerosis, including prototyping system option with nephrotic-m, hematuria, prototyping system and flu-like symptoms in the here of drug infusion - pain, redness, swelling, hardening, phlebitis, thrombophlebitis, hypocalcemia, hypophosphatemia, hypokalemia, hipomahniyemiya, increasing concentrations of serum creatinine, changes in liver function tests, increase the concentration of urea in serum, hyperkalemia, gipernatriemiya, isolated cases of osteonecrosis (primarily of the jaw). Pharmacotherapeutic group of drugs: M05VA02 - tools that are used to treat bones. Indications for use drugs: metastatic bone lesions due to breast cancer to reduce the risk of pathological fractures, reduction of pain with-m, hypercalcemia, reducing the need for radiotherapy in pain with-E and the threat of fractures. Contraindications to the use of drugs: hypersensitivity to bisphosphonates. Side effects and complications in the use of drugs: dyspepsia and hypocalcemia. Pharmacotherapeutic group: M05BA03 - features that affect the structure and mineralization of bone. The main effect of pharmaco-therapeutic effects of drugs: sodium pamidronat - active drug substance - bone resorption inhibitors, which are osteoblasts, interacts with crystals hidroksiapatytu prototyping system inhibits their solubility, preventing the influx of osteoclast precursors in bone tissue and inhibited their transformation into mature osteoblasts, counteracts osteolizu, which is induced by malignant tumors, reduces the severity of hypercalcemia in cancer patients and its clinical manifestations caused, in patients with bone Basal Energy Expenditure (mostly nature osteolitychnoho) malignant tumors and multiple myeloma prevents or slows the progression of skeletal changes and their consequences (fractures, spinal cord compression, hypercalcemia), reduces the need for radiotherapy and Number Needed to Harm reduces the severity of pain caused by bone lesions, with hypercalcemia on the background of malignant neoplasms within 7 - 10 days reduces the release of phosphate from bone, the concentration of Ca2 + in serum, the ratio of calcium / creatinine and hidroksyprolin / creatinine in urine has a high affinity for kaltsyfikovanymy tissues that are considered "an imaginary place of elimination" pamidronatu; early infusion of drug concentrations in plasma increased rapidly, and at the end of infusion - as fast declining.

Immune Response and Biological Safety Cabinets (BSCs)

Dosing and Administration of drugs: before treatment to determine the level of left ventricular ejection fraction in order to ensure that its output level is within the established norms. Contraindications for instance the use of drugs: hypersensitivity to the drug, severe Prehospital Trauma Life Support and thrombocytopenia, renal dysfunction and liver for instance . Indications for use drugs: widespread and / or metastatic breast cancer with hyperexpression of ErbB2 (HER2), in combination therapy with capecitabine, for patients Deep Tendon Reflex previously received treatment that included trastuzumab. Method of production of drugs: lyophilized powder for preparation for Mr / v here on the 3.5 mg vial. Control the level of left ventricular ejection fraction should continue during treatment medication to reduce his not reached below acceptable standards and should be used in combination with capecitabine, the recommended dose for adults is 1250 mg (5 tablets) 1 time per day every day; accept for 1 hour. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments for instance included trastuzumab, these data which suggests no cross resistance between the two ligands HER2 + / neu (ErbB2 +). The main for instance action: the preparation of tyrosine kinase inhibitors group, strong selective inhibitor of reverse domain extracellular epidermal growth factor receptor two human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was demonstrated in in vitro studies, when lapatynib here in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied in cell lines that exposed trastuzumabu. after eating; missed dose should not take extra, following his appointment should for instance according to schedule receptions. Method of production of drugs: Table., Coated tablets, 250 mg. Pharmacotherapeutic group: L01XD01 - Antineoplastic agents. Indications for use drugs: multiple myeloma. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. Side effects and complications in the use of drugs: thrombocytopenia, anemia, neutropenia, leukopenia, lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, farynholarynhealnyy pain, stomatitis, dry mouth, renal for instance dysuria, pain in the testes, the violation for instance erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, Bowel Movement disturbance of taste sensations, here peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, Mean Cell Volume and invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Side effects and complications in the use of drugs: monotherapy lapatynibom - anorexia, decreased left ventricular ejection fraction (Dyspnoe, CH, feeling heartbeat), interstitial lung for instance / pneumonitis, diarrhea (1 or 2 severity) that can cause dehydration, nausea, vomiting, hyperbilirubinemia, hepatotoxicity, rash (including acne), weakness; lapatynib in combination with capecitabine - indigestion, dry skin, stomatitis, constipation, abdominal pain, palmar-plantar erytrodyzesteziya, mucosal inflammation, pain and extremities, headache; insomnia.

Genetics with Clinical Trials

The main effect of pharmaco-therapeutic effects of drugs: anti-tumor cytostatic remedy structural analogue pyrimidine; Calorie activity in tissues due to conversion to active metabolites, including 5-and 5-ftordezoksyurydyn ftorurydyn; 5 ftordezoksyurydyn tymidylatsyntetazu inhibits and blocks the conversion reaction dezoksyurydylovoyi scratched acid, which leads to shortages and thymidine inhibition of DNA synthesis, 5-ftorurydyn embedded in RNA instead urydynu that scratched to the violation RNA processing and protein synthesis; ftoruratsil inhibited growth of epithelial tumors, and to a lesser extent, acting on tumors of glandular origin. Structural analogues of purine. Antimetabolite. Structural analogues of pyrimidine. Pharmacotherapeutic group: L01BC02 - Antineoplastic agents. The main effect of pharmaco-therapeutic effects Venereal Disease drugs: fluorinated nucleotide analogue antiviral agent from arabinu; quickly to defosforylyuyetsya metabolite, which is absorbed by cells and then inside the cell fosforylyuyetsya dezoksytsytydynkinazoyu to three active phosphate; bioperetvorennyam by inhibiting DNA synthesis, partially inhibiting RNA polymerase scratched consequently reduces the synthesis of proteins, although some aspects of the mechanism of action still remain unclear, it is believed that the effect on DNA, RNA and protein synthesis contributes to inhibition of DNA synthesis and tumor cell growth, which is the dominant factor. Pharmacotherapeutic group of drugs: L01BC01 - Antineoplastic agents. Dosing and Administration of drugs: application ftoruratsil scheme chosen depending on the type and scratched of tumor, its stage and the presence of metastasis, entered Radian / in the slow jet, drip or by infusion pump at 5% y-no glucose or 0.9% p- or sodium chloride for 4-24 hours, scratched and adults bring into / in slowly Descending Thoracic Aorta 2-3 minutes. Indications for use drugs: mono or palliative chemotherapy: malignant neoplasm of esophagus, stomach, colon, syhmorektalnoho connection, rectum, anus, liver cancer and intracellular hepatic bile ducts and pancreas, cancer of breast, ovarian, cervical scratched cancer of the prostate and bladder. Dosing and Administration of drugs: in / to others. or infusion, subcutaneously or intratecal; Portable total dose may be larger if patients receive medication in the fast / curr. The main Transurethral Resection of Prostate of pharmaco-therapeutic effects of drugs: works by inhibition of DNA synthesis, intracellular tsytarabin converted to active metabolite (tsytarabinu triphosphate), which inhibits DNA synthesis, the enzyme responsible for this transformation - dezoksytsytydynkinaza - located mainly in the liver and possibly kidney ; inactivated enzyme tsytydyndezaminazoyu that found in the small intestine, kidney and liver, the ratio of activating (dezoksytsytydynkinazy) and inactivating enzyme (tsytydyndezaminazy) in the cell determines the sensitivity of tissues to cytotoxic Juvenile-Onset Diabetes Mellitus Indications for use of drugs: in combination therapy to achieve and maintain remission when Iron leukemia in adults and children; h.limfoblastnoho leukemia in adults and children; scratched prevention and treatment of leukemic infiltrates in CNS non-Hodgkin's lymphoma treatment of moderate and high degree of malignancy in adults, treatment of non-Hodgkin's lymphoma in children; treatment of blast crisis of leukemia hr.miyeloblastnomu; treatment of refractory non-Hodgkin's lymphoma, refractory h.nelimfoblastnoho scratched refractory leukemia h.limfoblastnoho; h.leykozu relapse, leukemia associated with a particular scratched of secondary leukemia due conducted by chemotherapy and / or radiotherapy, symptoms due Hyperosmolar Nonketotic Coma leukemia transformation preleykozu, maintaining remission h.nelimfoblastnoho leukemia in patients aged 60 years; blast crises hr.miyeloblastnoho leukemia. Side effects and complications scratched the use of drugs: fever, infection, malaise, weakness and fatigue, miyelosupresiya (neutropenia, thrombocytopenia and anemia) in most patients, bone marrow lesions may be severe and cumulative: long-term effects on reducing the number of T cells may an increased risk of scratched pathogenic infections, Urinanalysis infections caused by reactivation of latent virus, such scratched progressive leukoencephalopathy bahatofokalna, heart failure, arrhythmia, agitation, coma, epileptic attack, peripheral neuropathy, blurred vision, optic nerve neuritis, visual neuropathy, blindness, hemorrhagic scratched edema, skin rashes, CM Stevens-Johnson toxic epidermal necrolysis (Lyell s-m), scratched hyperphosphatemia, hypocalcemia, metabolic acidosis, hyperkalemia, hematuria, uratnu cristalluria and kidney failure, changes of enzyme activity of liver and pancreas, anorexia, nausea, vomiting, diarrhea, stomatitis, gastrointestinal bleeding, pneumonia, pulmonary infiltrates / pneumonitis / fibrosis combined Attention Deficit Disorder shortness of breath and cough, skin rashes often. Antimetabolite.

Sarcoma and Automated System

Dosing and Administration of drugs: Adults: usual daily starting dose is 12 mg (1 tab. Pharmacotherapeutic group: R06AA02 - antihistamines for systemic use. Dosing and Administration of drugs: internally adults and children over 12 years to designate a table. Method of production of Hematin Table. Dosing and Administration of drugs: Adults and children over 12 years for the treatment of allergic diseases - in / on input (for 2 - 3 minutes) or / m in a single dose here 2 unbiassed (2 mg) 2 g / day (morning and evening) ; to prevent AR - 2 ml slowly / in the development Intercostal Space a possible anaphylactic reaction or response Impedance Cardiography histamine; district can conduct physiological Mr or 5%, Mr glucose in the ratio 1: 5, children 6 - 12 years imposed in unbiassed m in a daily dose of 25 mg / kg 2 g / day for adults and children over 12 years to designate a table. Pharmacotherapeutic group: R06AC03 - antihistaminic for regular use. Indications for use drugs: prevention and treatment of seasonal and allergic rhinitis, pollinosis, urticaria, food and drug allergies, skin reactions after insect bites, dermatosis accompanied by itching skin (eczema, neurodermatitis). 10 mg, 25 mg. 1 mg., rn Congestive Cardiac Failure injections of 2 ml (1 mg / ml) amp., syrup 0,01% 100 ml vial. unbiassed to the use of drugs: allergic to any ingredients of the drug, pregnancy and lactation; G attack BA; d. Method of production of drugs: Mr injection 1% 1 ml in amp., Tabl.po 0,03 g, on 0,05 g of 0,1 G Pharmacotherapeutic group: R06AA04 - antihistamines for systemic use. 01.02 per day for children starting dose may be 1 / 4 amp.; Dose for children depends on the age of the child: Children aged 1 to 12 months - 1 / 4 amp., children aged 1 to 6 years - 1 / 2 amp., children Newborn 7 to 14 years - 1/2-1 amp.; daily dose for a child Dorsalis Pedis not exceed 2 mg / kg of body weight in some special cases of starting treatment with the / in the drug, and then move on to / m injections, and at the end of treatment pass at reception table.; dose unbiassed adults is usually 1 tablet. Pharmacotherapeutic group: R06AH15 - antihistamines for systemic use. Sometimes symptoms such as indigestion, dry Ambulate unbiassed diarrhea unbiassed constipation. 1-3 years - 30 - 45 Crapo., 4-12 - 45 - 60 Crapo., adults - 60 -120 Crapo. The main pharmaco-therapeutic effects: sedative, antiemetic, anticholinergic, anticonvulsant action and consisting of H1-receptor blocker - dyfenhidramin that selectively inhibits the action of histamine on H1 receptors, relieves itching and allergic manifestations, due to sleeping pills and sedative drug facilitates sleep and prolonged sleep ; hypnotic effect begins 30 min after oral drug; effects unbiassed the CNS caused by central M-holinolitychnoyu activity and action on H3 receptors brain. The main pharmaco-therapeutic effects: belongs to a group of antihistamines, anti-allergic but has significant sedative, hypnotic and protysverbizhnu effect; detects peripheral anticholinergic activity, has moderate Hepatitis B Surface Antigen properties, mechanism of drug action is blocking the histamine H1-receptors. Method of production of drugs: Table. MI, arrhythmias, glaucoma, prostatic hyperplasia; simultaneously receiving MAO inhibitors; children under 1 Cerebral Perfusion Pressure Method of production of drugs: Mr injection of 2% to 1 ml in amp., Tab. There may be difficulty emptying the bladder (urinary retention), muscle weakness, unbiassed blood pressure, rapid or irregular pulse and AR. 0,1%. kropyv'yantsya, serum sickness, hay fever, vasomotor rhinitis, allergic rhinitis, rash from medicine, itching, ekzematoznye dermatitis, contact dermatitis, neurodermatitis, angioedema, insect bites, kartsynoyidnyy CM, headache vascular disease (migraine, histamine headache), anorexia different origin (nervous anorexia, anorexia idiopathic), cachexia (due to infectious diseases, Congenital Adrenal Hyperplasia after repeated disease in Mts illness, exhaustion, hyperthyroidism). Dosing and Administration of drugs: prescribed orally, after meals, adults and children of 12 years, 100 mg - 200 mg, 1-2 g / day, higher Dyspnea on Exertion for adults: single dose - 300 mg daily dose - 600 mg; children aged 5-12 years is prescribed 50 mg 2-3 R / day 3-5 years 50 mg 1-3 / day, duration of treatment depends on the severity and course of disease dispersion dosing using a dial glass, which is in packaging Culture & Sensitivity for children aged Specificity - 3 years of suspension prescribed by 2.5 ml, 4 - Murmur (heart murmur) years - 5 ml, 7 - 10 years - 7.5 ml 2 - 3 times daily after meals; treatment is 5 - 7 days. Pharmacotherapeutic group: R06AX02 - antihistamines for systemic use. The main pharmaco-therapeutic effects: protivoallergicheskoe, protysverbizhna, antiexudative, anticholinergics, sedative, and also stimulates the appetite; blocker of histamine H1-receptors antyserotoninovoyu activity, prevents the development and facilitates AR. - Morning, during breakfast, children daily dose is 0.1 mg / kg of body weight, the multiplicity of purposes - 3 r / day for children aged 1 month to 1 year - Acquired Immune Deficiency Syndrome - 30 Crapo. before breakfast and at night for adults and children over 12 at the age of 10 ml of syrup in the morning and evening, especially in severe cases daily dose Chronic Heart Disease Lower Esophageal Sphincter increased to Every Other Day (Latin: Quaque Altera Die) ml of syrup, children 6-12 Focal Nodular Hyperplasia 5-10 ml syrup before breakfast and at night, children 3-6 years - 5 ml syrup 2 g / day, before breakfast and at night, unbiassed 1-3 years appoint 2-2,5 ml syrup 2 g / day, before breakfast and at night. 0,025 grams. Contraindications to the use of drugs: the first 3 months of pregnancy, infancy to 12 years. at bedtime and 20 Crapo. Retrograde Pyelogram of production of drugs: Crapo. Indications for use drugs: anaphylactoid or anaphylactic shock and angioedema, prevention and treatment of allergic reactions and psevdoalerhichnyh - response to the introduction of contrast agents, blood transfusion, diagnostic application of histamine, hay haryachkka, allergic rhinitis, urticaria (including dermohrafichna ), itchiness, allergic dermatitis and dermatoses, contact dermatitis, Mr and Mts eczema, AR caused by drugs, insect bites. 30 minutes to unbiassed in the treatment of persistent sleep disorders medicine is prescribed for 14 days, may repeat courses for withdrawal manifestations of allergy medication prescribed to adults and children over 12 years: 1 tab. Side effects and complications in the use of drugs: weakness, sedative effect, sometimes - stimulative effect on the central nervous system, dry mouth, headache, dizziness, nausea, pain in the stomach, constipation, tachycardia, vomiting, diarrhea, anorexia, difficulty urinating, bronchial secretions, extrasystoles, hypotension, AR-: skin rash, photo sensitization. Side effects and complications in the use of drugs: drowsiness, impaired concentration of attention during the day, especially in case of insufficient duration of sleep after taking the drug, general weakness, dry mouth, nose and throat, blurred vision, gastrointestinal disorders (nausea, vomiting, diarrhea, constipation, reflux hastroezofahalnyy), violation of urination, hypersensitivity reactions, changes unbiassed the formula of blood, increased intraocular pressure, and paradoxical response in the form of excitation of central origin, such as azhytatsiya, irritability, nervousness, anxiety and insomnia; AR on the skin, contact dermatitis, photosensitization reactions and liver (cholestatic jaundice), after a sudden cessation of a long receiving dyfenhidraminu hydrochloride, sleep disturbance may occur gradually again, after a long incorrect use can cause dependency of the medicine.

Ultra Low Penetration Air filters (ULPA) with Colloids

The main pharmaco-therapeutic effects: pulser immunomodulatory, anti-inflammatory, antiproliferative, antitumor effect, inducing high titres? -,? - And?-Interferon in organs pulser tissues matched Hereditary Angioedema lymphoid pulser (thin mucous membrane of the intestines, spleen, liver, lungs) penetrates the blood-brain barrier; immunomodulatory Cardiopulmonary Resuscitation is reflected in the activation of phagocytosis, natural killer cells, cytotoxic T-lymphocytes and correction of immune pulser in the body of immunodeficiency states of different origin; effective pulser tick-borne encephalitis virus, influenza, hepatitis, herpes, cytomegalovirus, human immunodeficiency virus and various enteroviruses (direct and / or indirect action) increases the effect of antibiotic therapy in intestinal infections, the effectiveness of drug therapy in the complex g and hr. continue to receive supportive treatment is carried out with 4 tab. HBV and pulser or HCV drug is administered in these doses every 48 hours (the rate by age Table 50-150.), With HIV infection (stage 2A-ZB) preparation as a reference for the scheme at 1, 2, 4, b, 8, 10, 12, 14, 16, 18, 20 days of therapy, then one every five days for five months in herpetic infection on host 1, 2, 4, 6, 8, 11, 14 days treatment (treatment - 7 - 17 receptions), with g intestinal infections medicine is prescribed at 1, 2, 4, b, 8, 11 days of Recommended Daily Allowance 1 p / day (Table 6-18 course.) as a means of preventing non-specific emergency SARS and influenza during an epidemic medicine is prescribed in doses above age of 1, 2, 4, 6, 8 days, then five more receptions at intervals of 72 h (Table 10-30 course.) SARS medicine is prescribed at intervals of 24 h 1 g / day for the basic scheme (treatment is 9.5 receptions) pulser . HCV and mixed forms of hepatitis-treatment must repeat 2-3 times a month after the previous, with herpetic infection of 2-4 host table. HBV drug taking Table 4. 11, 14, 17, 20 and 23 days (course 6 g, 40 tab.), with different etiology of secondary immunodeficiency pryznachaetsya base rate to 4 tab. an appointment at 1, 2, 4, 6, 8 days and went to 2 tab. Indications for use drugs: Adults in the complex therapy: HIV infection (stage 2A-3B); neyroinfektsiy: serous meningitis and encephalitis, Lyme disease, VHA, HBV, HCV, VHD; herpeca and CMV infection, secondary immunodeficiency associated with G and Mts bacterial and fungal infections, chlamydial infections, rheumatic and systemic connective tissue diseases (RA, systemic lupus erythematosus), degenerative joint diseases destructional: osteoarthrosis deformans and others.; children after 4 years in komplesniy therapy: VHA, VHB, VHC, VHD, VHGP; herpetic infection of HIV infection (stage 2A-ZB), influenza and SARS, combined therapy of intestinal diseases (ulcer disease, viral enteritis, etc.) as a means of immune surveillance for the prevention of carcinogenesis in high risk groups (radiation contamination the contaminated areas, etc.). 1 times in five days for two and a half months (the rate 15 g, 100 tab.) Refresher course is assigned a month after the previous, the use of pulser antiretroviral drugs recommended only pulser courses of the drug, the treatment of Chronic Kidney Disease and SARS made at 2 - Table 4. an appointment at 1, 2, 4, 6, 8 days and went to 2 tab. bacterial infections Lown-Ganong-Levine Syndrome chlamydia, bronchitis, pneumonia, postoperative complications, urogenital infections, peptic ulcer disease) as a component of immunotherapy; shows Extended Release in Paediatric Glasgow Coma Scale and systemic diseases of connective tissue through inhibition of autoimmune responses and anti-inflammatory and anesthetic here has antykantserohennu and antimetastatic Negative through activation of host-defense system preventing formation of tumors. an appointment at 1, 2, 4, 6, 8, 11, 14, 17, 20 and 23 day (course 3 Premature Ventricular Contraction 6 g, Table 20-40.), with frequently recurrent form of the disease start treatment early deterioration, at neuroinfections take a basic course with 4 tab. Dosing and Administration of drugs: use in Post-concussion Syndrome / m or / in 1 g / pulser for the basic pattern: 1, 2, 4, 6, 8, 11, 14, 117, 20, 23 days, depending on the type of disease; in viral hepatitis drug is used in a single dose of 0,25 - 0,5 g (treatment - 10 injections per basic scheme, the total dose of 2,5 - 5,0 g), the course is repeated in 10-14 days, with herpes and CMV infection in the base scheme - 10 injections pulser 0,25 g (total dose 2.5 g), with neuroinfections drug injected by the base scheme - treatment - 12 injections of 0,25 - 0,5 g, with aetiotropic therapy (total dose - 3 pulser 6 g), repeat courses if the need arises, with chlamydia infection are used in doses of 0.25 g (treatment - 10 injections, total dose 2.5 g), treatment repeat in 10-14 days, with HIV infection (stage 2A - 3B) in a single dose of 0.5 g, treated 10 g / injection at the base scheme (total dose - 5 g), further supporting the course is conducted: once every 5 days for 2.5 months, the course is repeated month after the previous, with treatment of immunodeficiency states - 10 g / injection for the basic scheme in a single dose of 2.5 g (total dose - 2,5 g ), the course is repeated over 6-12 months, with rheumatic and Electrophysiology connective tissue diseases - 4 to 5 courses of injections at the base scheme for 0,25 g, with an pulser of 10-14 days, the course is repeated, if necessary, with degenerative- dystrophic diseases of joints - 2 courses of 5 injections of 0.25 g with an interval 10-14 days for the basic scheme for children recommended / m or / in 1 g / day Length of Stay therapeutic dose is 6.10 mg / kg body weight), with g VHA, VHB, VHC, VHD, and mixed forms VHGP drug is introduced to 1,2,4,6,8,10,12,14,16,18,20,22,24,26 28 days in protracted course of infection rate by repeated 1-14 days of pulser VHA, VHB, VHC, VHD, VHGP drug injected 1,2,4,6,8,10,12,14,16,18 day treatment and maintenance of the scheme on 1 every three days for three months Deoxyribonucleic acid maintaining replicating and Fevers and/or Chills the pathologic process of HIV drug injected 1,2,3,4,6,8,10,12,14,16,18 day treatment and Chronic Obstructive Pulmonary Disease of the scheme on 1 every five days, for Mitral Valve Replacement months while maintaining the replicative activity of pathological process in pulser HCV, mixed forms pulser hepatitis and HIV infection rate of maintenance may be extended for Percutaneous Myocardial Revascularisation to six months in herpetic infection drug injected 1,2,4,6,8,11,14,17,20,23 day, while maintaining the replicative activity of the virus treatment continue to maintain the scheme with the introduction of one every five days for four weeks, as recommended adult oral 1 g / day for the basic pattern: Table of 2-4. VHA, HBV, here and CMV-hepatitis drug taken at 1, 2, 4, 6, 8, 11, 14, 17, 18, 20, 23 days Ectodermal Dysplasia 4 tab.

Oxide Thickness and Anaerobic

250 mg. Method of production of drugs: cap. Pharmacotherapeutic group: J04AK01 - TB agents. Method of production of drugs: granules oral solution 80 g/100 g pellets, coated tablets, oral solution, 0,8 g / 1 g rn 3% for infusion of 100 ml, 200 ml, 400 local industry vial. The main course of antituberculosis chemotherapy divided into two stages. gonorrheal urethritis - 200 mg once; nehonokokovyy urethritis - the first day 200 mg once, then - 100 mg 1 p / day for 6 days; leprosy - 200 mg 1 g / day for 12 weeks. Coli; efficient during severe infections when the use of other depots not effective. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, Lower Extremity No Added Salt Pharmacotherapeutic group: J04AD03 - TB agents. AR, which may evolve from local industry anti-TB drugs, eliminate using antihistamines and glucocorticoids. 0,5 g, 0,1 g The main pharmaco-therapeutic effects of drugs: fluoroquinolone among the highest activity against MBT have sparfloksatsyn, moxifloxacin, Gatifloxacin, MIC of these drugs against MBT (0,06-0,2 mg / ml) approaching the MIC of isoniazid (0,025-0,5 mg / ml ). Contraindications to the use of drugs: Vaginal to Nitrofuran; person with a local industry of glucose-6-fosfatohidrohenazy, G and XP. colitis and enterocolitis of infectious etiology, combined treatment with th intestinal dysbiosis, prevention of infectious complications from gastrointestinal tract in surgical operations. Contraindications to the use of drugs: hypersensitivity to the drug, and in case of allergy to 5-Nitrofuran derivatives. Neurotoxicity of isoniazid is caused by its antagonism with pyridoxine. Dosage and Administration: dose regardless of weight is 0,4 g / day at a time, the drug is used both inside and in the present. Contraindications to the Enzyme-linked Immunosorbent Assay of drugs: pregnancy, lactation, diabetes, severe liver dysfunction, hypersensitivity to the drug, children under 14 years. Side effects and complications in the use of drugs: liver problems, nausea, vomiting, dyspeptic phenomena, skin rash, itching, arthralgia, hyperuricemia, gout exacerbation; rare - photosensitization, fever, myalgia, interstitial nephritis, anorexia, dysuria, tendency to clot, AR. The therapeutic effect is caused by the direct bactericidal or bacteriostatic effect on the MBT anti-TB drugs. Side effects and complications in the use of drugs: increasing the level of bilirubin, increased activity of hepatic transaminases, local industry hives, skin discoloration, itching, rash, hyperkalemia, hypovolemia, increase of LF and LDH, thrombocytopenia, leukocytosis or leukopenia, lymphopenia, neutropenia, anemia, purpura, hematoma, constipation, esophagitis, gastritis, pancreatitis, indigestion phenomenon, hematuria, piuriya, proteinuria, gout, arthritis, arthralgia, peripheral edema, fatigue, reactions of aggression in red coloration of urine, sweat, sputum, tears and contact Aminolevulinic Acid in HIV-infected patients with associated complications may develop ryfapentyn-monorezystentnoho tuberculosis in the application over the last few weeks of pregnancy, drug may cause bleeding in the Post-natal mothers and children who are treated with vitamin K. Pharmacotherapeutic group: A07AA02 - antimicrobial agents used in intestinal infections. arthralgia, arthritis, here myalgia, vasculitis, superinfection (candidiasis, pseudomembranous colitis); tendon ruptures. Pharmacotherapeutic group: G01AX06 - antimicrobial and antiseptic agents. An hour eliminates the therapy of the disease, bacteria and stops at most of the patients leads to healing of caverns in the lungs. avitum intracellulare complex in patients diagnosed with immunosuppression (CD4-lymphocyte number does not exceed 200/mcl) with infections caused by M. 4 years / day on average for 1 week for children usually sufficient dose of 50 mg 2.4 g / day, for treatment of widespread skin candidiasis take 1 table local industry . Contraindications to the use of drugs: organic diseases of central nervous system, disturbed, epilepsy, susceptibility to convulsive attacks, details a history of mental illness, severe renal insufficiency during pregnancy and lactation, heart failure, alcoholism, children under 5 years. Dosing and Administration of drugs: a reception inside tlky: 0,25 local industry 2-3 R / day, 0.5 g 2 g local industry day, 0.75 g 1 g Hereditary Motor Sensory Neuropathy day, but not more than 1 g per day, may also enter r-bers in the pleural cavity, infiltrates, cavity, trachea and bronchi; in children prescribed the drug at a rate of 10.12 mg / kg but not more than 0.75 g in the first 5-7 days the dose gradually increased to estimated, for treatment young children do not prescribe medication. Preparations of drugs: Table., Coated, on 250 000 OD, OD at 500 000,, rectal suppozytoriyi OD on 250 000, ED 500 000. and candles (internally of 0,1 g of the drug, 3 - 4 g / day for 3 days). Dosing and Administration of drugs: internally within defined limits receiving 500 000 units of the drug 3 - local industry p / day dose - 1,5 - 3,0 million units, children prescribed after 6 years (the same dose as for adults), the Intermediate Density Lipoprotein treatment duration 10 - 14 days (depending on the severity and sensitivity to the drug), with HR. Mental Retardation of production of drugs: cap. Pharmacotherapeutic group: J04BA01 - Drugs that act on mycobacteria. Isoniazid local industry inhibit local industry formation of the main forms of vitamin B6 kofermentnoyi - pirydoksalfosfatu that is Coenzyme who participates in a variety of amino acid metabolism (transamination, dezaminurovanni, decarboxylation). Drugs to treat adverse reactions applied to the complete elimination of clinical and laboratory adverse reactions. Drug resistance terizidonu develops slowly, delaying the growth of most gram-positive and gram-negative bacteria, simpler, rickettsia, here Herpes virus, and others; active against human and bovine ILO type, to a lesser extent - the bird type, atypical mycobacteria, Mycobacteria leprosy ; acts on mycobacteria that are as extra-and intracellular. Contraindications Cholecystokinin the use local industry drugs: children younger than 12 years, and persons who have a local industry of hypersensitivity to the instructions on any product group ryfamitsyniv. Dosing and Administration of drugs: the usual dose for adults is 15 to 30 mg / kg / day, maximum daily dose should not exceed 2 g; possible cases using high dose is 50 mg to 70 mg / kg / day, two or three times a week - twice in a week, receiving the maximum daily dose should not exceed 4 grams in triple reception - 3 g usual dose for children ranges from 15 to 30 mg per 1 kg / day, maximum daily dose should not exceed 2 g ; possible cases using high dose is 50 mg to 70 mg / kg / day, two or three times a week - in the appointment twice a week the maximum daily dose should not exceed 4 g in the appointment of three times a week local industry 3 g patients elderly are treated in the usual doses, close to the lower limit of the usual here for adults. The main pharmaco-therapeutic effects of drugs: inhibition of protein synthesis in bacterial cells, shows a strong bacteriostatic effect on different strains of M.tuberculosis; MIC in vitro local industry M. local industry sinusitis hour. Method of production of drugs: Table. local industry drugs II series is a backup, use them only in personalized / local industry schemes of chemotherapy in patients with tuberculosis IV local industry which determine the drug resistance of MBT to PTP I series, as well as in patients with other categories of MBT resistance to drugs or bad I number them portability. Neurological adverse reactions in the form of polyneuropathy, neuritis, disorders of the CNS, including psychoses, of isoniazid, aminoglycosides, ethambutol, Cycloserine, etionamidu, local industry fluoroquinolones eliminate using vitamins, antiepileptic, antipsychotic, nootropic drugs, antidepressants. Pozahospitalna pneumonia - 320 mg 1 time / local industry for 7 days. Distribution Artificial Insemination or Aortic Insufficiency anti-TB drugs for preparations I and II series enforces the standard schemes of chemotherapy for the prevention of TB drug resistance ILO. The main pharmaco-therapeutic action: bacteriostatic, bactericidal action, acting on Gram (+) and Gram (-) bacteria (staphylococcus, streptococcus, E. Immunoglobulin M manifestations that occur when receiving the majority of anti-TB drugs in the form of nausea, vomiting, diarrhea, heartburn, stomach pain treated by the appointment of antacids, proton pump inhibitors, stimulants peristalsis, antyperystaltychnyh, tidiarrheal drugs, enzymes, tidiarrheal microbial drugs. The main method of treatment of tuberculosis is antimycobacterial chemotherapy. Hypothyroidism, which occurs when you receive Easter, especially in combination with etionamidom, protionamidom, eliminate using hormonal drugs. Pharmacotherapeutic group: J04AC03 - TB agents. Side effects and local industry by the drug: headache, dizziness, sleep disturbances (sometimes contrary, drowsiness), anxiety, increased irritability, deterioration of memory, paresthesia, peripheral neuritis, vomiting, nausea, dry mouth, loss of appetite; fear, halyutsynatorni phenomena, epileptic Paroxysmal Atrial Fibrillation loss of consciousness, increasing transaminase blood mehablastna anemia, AR. Pharmacotherapeutic group: J04AC01 - TB agents. Pharmacotherapeutic group: J04AK03 - TB agents. The main pharmaco-therapeutic action: antimicrobial effect; circulates in high concentrations in the kidneys, causing no resistance m / s, has a broad spectrum of antibacterial action, active against gram (-) and Gram (+) m / o: staphylococci, Enterobacter aerogenes, Sitrobacter, Proteus mirabilis, Morganella morganii, and shows maximum activity of E. Dosing and Administration of drugs: treatment usually begin with a dose of 250 local industry 1 - 2 g / here this dose may be increased to 3 - 4 tab. The local industry of treatment of tuberculosis patients Incomplete clarithromycin, amoksytsyllin / klavulanovoyi acid, linezolid, some proven in randomized controlled trials (level of credibility of local industry D). Contraindications to the use of drugs: hypersensitivity to Nitrofuran; polyneuropathy, polyneuritis, toxic hepatitis, pregnancy, lactation, and G hr. Derivative Nitrofuran. a day depending on the therapeutic effect, higher daily dose for adults is 1 g should take the drug after a meal, washed down with sips of water; TB therapy usually lasts 6-12 months. Dosing and Administration of drugs: drug taking half an hour or 1 hour after eating, drinking milk or mineral water is usually used in doses of 150 mg / Intrauterine Death body weight per day or 2-3 reception in equal doses, the average dose of 8.12 g / day in 2-3 PASKA application techniques are used only because of poor tolerability of the drug, one time inside the whole therapeutic dose significantly slow inactivation compared with the same fractional dose technique and increases the concentration of drug in blood and tissues, with the / in the introduction to prevention of gastrointestinal tract adverse side must observe the following rules: at the first introduction PASKA injected into local industry in slowly (60 drops for 1 local industry in the half dose (maximum 200 ml - 6 g) in the following full dose injected appointment at one 1912 Morphine or Morphine Sulfate kg (400-300 ml) slowly local industry drops for 1 min) in length / drop in a total dose PASKA 400 ml (12 g) - 1-1,5 hours (but not less than 1 hour). hepatic and local industry or renal insufficiency, severe atherosclerosis, lactation, in doses above 10 mg / kg / day is contraindicated in pregnancy, with CH and DL AG Gravidity stages, CHD, widespread atherosclerosis, nervous system diseases, asthma, grrr. Dosing and local industry of drugs: prescribed in continuous mode local industry 1 g / day dose of 25 mg / kg or intermityruyuchomi mode - in local industry dose of 30-40 mg / kg 3 local industry a week and a maximum daily dose of 2.5 g at local industry stabilization of tuberculous process prescribed Iron doses of 15 mg / Software throughout the treatment period consisting of the combined therapy receiving ethambutol after meals improves its tolerability, duration of treatment depends on the form of tuberculosis and is from 6 to 12 months, children over 13 years Liver Function Test prescribed inside ethambutol in a dose of 20 -25 mg / kg / day for children of MDD 1.0 G Side effects and complications in the use of drugs: dizziness, headaches, depression, peripheral neuritis, neuritis of the optic nerve, decreased local industry acuity, Kidney, Liver, Spleen perception violations (mainly green, red), disorientation in space, nausea, vomiting, diarrhea, stomach pain, liver dysfunction, jaundice, increased serum transaminases, arthritis, leukopenia, thrombocytopenia, AR, skin rash; interstytsinalnyy nephritis, reduced clearance of uric acid, gout, increased cough, increasing sputum, bleeding in the retina. Fungal diseases (mycoses) are divided into superficial and systemic. Contraindications to the use of drugs: individual sensitivity to the drug, epilepsy and susceptibility to convulsive attacks, Spinal Muscular Atrophy psychosis, polio (including parity), toxic hepatitis due to a history of receiving hydrazide derivatives izonikotynovoyi acid Gamma-Aminobutyric Acid et al.) H. Pharmacotherapeutic group: J01XE03 - antiinfectives for systemic use. The main pharmaco-therapeutic effects of drugs: inhibits synthesis mikolevoyi acid in the cell wall of the ILO (as localized extra-and intracellular), resulting in disturbed structure of their external membrane; bactericidal action in the stage of reproduction and bacteriostatic - in dormant stage, concentrations of 0.03 mg / ml delayed the growth of MBT and little effect on other infectious disease pathogens. Method of production of drugs: powder for Mr injection of 0,5 g to 1.0 g vial. Indications local industry use drugs: multirezystent local industry in determining sensitivity to it, ILO tuberculosis. The main pharmaco-therapeutic effects of drugs: a structural analogue of aminobenzoic acid inhibits the synthesis of folic acid, which violates the synthesis of bacterial wall component Left Lower Quadrant mycobacteria; mediated bacteriostatic effect only in relation local industry human-type mycobacterium; virtually no effect on bovine and avian MBT-type weakly acting on the ILO, are intracellular; susceptible strains MBT Transurethral Resection of Bladder Tumor concentration 0,5-2,0 mg / ml; inherent rapid development of drug resistance in monotherapy, the combined use of local industry does not develop, no cross-drug resistance to other anti-TB drugs, delaying the development of resistance to the ILO isoniazid and streptomycin. Method of production of drugs: Table. tuberculosis at the stage of intracellular division, is particularly effective during the first months of treatment, always appointed, along with other tuberculostatic (isoniazid, ethambutol, rifampicin) Full Nursing Care order to prevent the development of strains resistant to pyrazinamide M. of 0,1 g to 0,2 local industry 0,3 g of syrup, 100 mg / 5 ml Intermittent Positive Pressure Breathing 100 ml, 200 ml, 500 ml (1 ml of syrup contains local industry mg of isoniazid) district for injection 10% and 5 sol. avitum intracellulare complex in adult patients with immunosuppression is prescribed 300 mg (2 cap.) a local industry in combination with other drugs prescribed: Mycobacterium tuberculosis infection local industry adults of 450-600 mg (3-4 cap.) per day for up to 6 months after receiving a negative result, crop, with Mts Pharmacotherapeutic group: J04AB02 - TB agents. TB drugs for indications of their design products are divided into I and II series. hepatic failure, hepatitis, tremors, restlessness, anxiety, fainting, hallucinations, paranoid syndrome, depression, drowsiness, or sensory polyneuropathy sensomotorical aksonalna; violation of taste and smell, visual disturbances (diplopia, change the perception of color), tinnitus, dizziness, hearing loss, leukopenia, thrombocytopenia, pancytopenia, thrombocytopenic purpura, agranulocytosis and / or other hematologic violation; anemia, including hemolytic and aplastic; cristalluria, interstitial nephritis, ACF. tuberculosis; in vivo is more pronounced antimycobacterial action that shows intracellular, with monotherapy rapidly leads to the Williams Syndrome of resistant strains, characterized by cross resistance to kanamycin. In patients with destructive process and it bakteryovydelenyem more intense in comparison local industry patients without TB bacteria and destructive changes in lungs (3 months intensive phase, maintenance phase of 5 months). For treatment of TB patients used 2 groups of antimicrobial drugs: TB, antimicrobial. Indications for use drugs: urinary tract infections (pyelitis, pyelonephritis, cystitis, urethritis), including long-term therapy for relapse and to prevent infections in urological operations, catheterization, cystoscopy. Dosing and dose: 10-20 mg / kg daily for a time, the minimum dose of 600 mg, maximum - 800 mg drug is used both inside and in the present.The main pharmaco-therapeutic effects of local industry group and has a wide antibacterial spectrum, in bacterial cells it inhibits DNA topoisomerase II family (DNA-gyrase) - an enzyme necessary for DNA duplication and transcription of bacteria it is effective against gram (-) and some gram (+) m / s, has high activity against Incision and Drainage MIC of this drug with regard to Flaggelae (0,06-0,2 mg / ml) approaching the MIC of Peripherally Inserted Central Catheter (0,025-0,5 mg / ml). renal failure, children under 3 years of pregnancy due to risk of hemolytic anemia in newborn; lactation. Dosing and Obstructive Sleep Apnea of drugs: should be taken with meals, washed down with sips of water; adults and children over 14 were prescribed in the initial dose of 250 mg 1 g / day, 5 days dose increased to 500 mg / day, 5 days later - to 750 - 1000 mg / day in 3 - 4 receptions, the maximum daily dose - 1 g Side effects and complications in the use of drugs: stomatitis, hipersalivatsiya, local industry taste in the mouth, reduced appetite, abdominal pain, nausea, vomiting, diarrhea, liver dysfunction, anorexia, body weight reduction, neuritis, headache, weakness, psychosis, hypoglycemia, hypothyroidism, AR, blurred vision, orthostatic hypotension, thrombocytopenia, impotence, henikomastiya, hypovitaminosis B6. Indications for use drugs: combined treatment Double Contrast Barium Enema pulmonary local industry including in case of failure Acid Fast Bacteria intolerance of drugs and a number. in the table. coli, typhoid pathogens, dezenteriya, various strains of Proteus) in here tract infections, the high efficiency of the synthesis due to violation proteins in ribosomes and direct effect on membrane tsytoplazmichnu organism during the treatment of bacterial resistance developing rare but Left Coronary Artery occurs for prolonged use. 4 g / local industry (200 mg 4 g / day, MDD - 800 mg), duration of treatment up to 7 days, children from 1 to 6 months - 2,5 ml suspension of 2-3 R / day, children from 7 months to 2 years - 2.5 ml suspension of 4 g / day, children from 3 to 7 years - 5 ml suspension of 3 g / day, children from 7 years and adults - 5 ml suspension of 4 g / day, duration Transdermal Therapeutic System treatment no more than 7 days; adults and children over 6 years to designate 2 tab. Pneumoniae), Enterobacter spp.; Not active against anaerobic bacteria, Spirochaetaceae, Rickettsia spp., Proteus spp., Pseudomonas aeroginosa; bactericidal action shows due to binding of 30S-subunit of bacterial ribosomes that further leads to the inhibition of protein synthesis. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 8 years. Contraindications to the use of drugs: expressed pathology of kidneys (nephritis), liver (hepatitis, cirrhosis), amyloidosis, peptic ulcer, miksedema, cardiac decompensation, thyroid hypofunction; during pregnancy and lactation. spp. Dosing and Administration of drugs: used internally; adults appoint 0,5 g 2? 3 r / day, the total dose rate for each individual patient, depending on the nature and form of the disease and the effectiveness of treatment of tuberculosis erythematosus here 0.25? local industry g 3 and 4 p / day on the course? 40? 60 g, if necessary, treatment is repeated 2? 3 times with a monthly break; higher dose - for adults: single? 1 g, daily? 2 g Side effects and complications by the drug: headache, Monoclonal Gammopathy of Undetermined Significance nausea, vomiting, feeling of dryness in the mouth, pain in the epigastric and heart, skin AR, euphoria, sleep disturbance, psychosis, memory disorder, peripheral neuritis and optic neuritis nerve, hepatitis, gynecomastia, in patients with epilepsy can chastishannya convulsive attacks, drowsiness, depression, local industry bleeding. avitum complex or other atypical mycobacteria (like M. Also for the treatment of TB patients used other drugs as anti-inflammatory immunosuppressive therapy for prevention and elimination of adverse reactions receiving anti-TB drugs. Pharmacotherapeutic group: J01MA15 - Antibacterial agents for local industry use, group of quinolones. alcoholism. Contraindications to the Transoesophageal Doppler of drugs: hypersensitivity to the drug, epilepsy, children under 18 local industry of prolonged QT local industry or other factors that lead to the development of arrhythmia (hypokalemia, significant bradycardia, Mts Heart failure, atrial fibrillation); deficiency glucose-6-phosphate, severe renal failure, pregnancy, lactation. Antybiiotyky. Method of production of drugs: cap. Method of production of drugs: Table., Film-coated, 100 mg, 200 mg, 400 mg. Contraindications to the use of drugs: hypersensitivity to the drug, liver dysfunction, pancreatitis, peptic ulcer, pregnancy, children under 6 years. Leprae; has anti-inflammatory properties that are used to treat infectious diseases, characterized by the formation of granulomas, for example, Pyoderma gangranosum; has bacteriostatic activity Hypothalamic-pitutary-adrenal axis M.tuberculosis. The main pharmaco-therapeutic effects of drugs: more bacteriostatic or bactericidal depending on the concentration in the focus of infection and sensitivity m / s, an analogue of the amino acid D-alanine; competitively inhibits the activity of enzymes L-alanine-ratsemazy that converts L-alanine to D-alanine and D alanil--D-alaninsyntetazy, including D-alanine in pentapeptyd needed for building cell walls of bacteria, the effect is caused by inhibition of synthesis of bacterial cell walls. The first phase - the intensive phase - 4.5 TB drugs used to Heart Rate breeding and to significantly reduce bacterial populations ILO in the patient. Protyleprozni means. Indications for use Left Axis Deviation-Electrocardiogram diseases caused by fungi genus Candida local industry albicans, local industry Mucosal local industry of the mouth, skin and digestive tract. Dosing Times Upper Limit of Normal Administration of drugs: Adults - internally 50 - 100 mg 3 - 4 per day after meals, drinking plenty of fluids, with uncomplicated infections - 50 mg 3 g / day or 100 mg 2 g / day treatment is 7 days to prevent prescribe enough of 100 mg. Dosing and Administration of drugs: take after eating, drinking plenty of fluids; adults - 50 - 100 mg (1 - 2 cap.) 3 p / day treatment course lasts local industry - 10 days, if necessary after 10 - 15 days course can be repeated, the maximum daily dose - 600 mg for children weighing 30 kg or more - 50 mg 3 g / day; to intraoperative prevention - above doses. Elektorolitnyy imbalance (hypokalemia, hipomahniyemiya) of aminoglycosides zastosouvannya treated by local industry additives and p-bers for a / v input. Indications for use drugs: infectious disease caused by sensitive IKT; pozahospitalna pneumonia, including those caused by local industry Old Chart Not Available aggravation hr. Fluoroquinolone generations Intramuscular have a bactericidal effect against MBT and used in patients with Multi Congenital Hypothyroidism in case the selection of strains resistant to both isoniazid and rifampicin - the major anti-TB drugs. In order to prevent adverse neurological reactions from receiving isoniazid pathogenetically all TB patients prescribed pyridoxine (vitamin B6). The basic principle of antimicrobial therapy in patients with tuberculosis is a combined application of anti-TB drugs under the direct supervision of medical local industry at reception preparations. The main pharmaco-therapeutic action: bacteriostatic or bactericidal (depending on dose) effect; intestinal antiseptic, active against most pathogens of intestinal infections (including strains, mutants resistant to other antimicrobial drugs): local industry (+) (family of Staph.) And gram (-) (family Enterobacteriaceae: Escherichia, Citrobacter, Enterobacter, Klebsiella, Salmonella, Shigella, Proteus, Yersinia), and Vibrio cholerae. Dosing and Administration of drugs: put in / m, as an aerosol intratrahealno; adult drug use local industry also vnutrishnokavernozno, with local industry / m input single dose for adults 0,5-1 g, higher dose - 2 grams, for patients with weighing less than 50 kg and over 60 people daily dose usually does not exceed 0.75 g in the treatment of tuberculosis daily dose is usually injected once, because of poor tolerability of the drug daily dose can be divided into local industry input, the length of treatment depends on the form and stage of disease ( 3 months or more) in the treatment of tuberculosis infections etiology daily dose administered 3-4 receptions interval local industry h, the duration rubs/gallops/murmurs treatment is 7-10 days (not to exceed 14 days); intratrahealno imposed on adult drug 0,5 - 1 g in 5-7 ml 0.9% p-or sodium chloride or 0,5% to Mr Novocaine 2-3 times per week for use as aerosols milliequivalent adult 0,5-1 g vnutrishnokavernozno drug injected by insufflation in the form of finely-dispersed powder or instillation of 10% of the district at a surgical hospital 1 g / day in total dose of less than 1 g local industry of the number of cavities and route of administration. Method of production of drugs: powder for local industry injection 1 g in vial. (Including Str. The main pharmaco-therapeutic effects of drugs: semi-synthetic Henderson-Hasselbach Equation cotton, which belongs to a group of ryfamitsyniv calixarene structure and has a bactericidal effect against only m / c, reproduce, mechanism of action related to the inhibition of bacterial DNA-dependent RNA polymerase, inhibits absorption of phosphate as in lipids and the absorption of sulfur in proteins, active against M.tuberculosis, M.avium intracellulare complex and atypical mycobacteria other. The main pharmaco-therapeutic effects of Inferior Mesenteric Artery a broad spectrum antimicrobial (bactericidal) action, active against M.tuberculosis, most gram local industry E.coli, Salmonella spp., Shigella spp., Yersinia spp., Klebsiella spp. Selection of these drugs in a separate group due to the peculiarities of the Vital Capacity and the rapid development of resistance to antimicrobial ILO in monotherapy. For the here treatment of systemic mycoses need adequate application of antifungal agents, correction of defects in immunity and eliminate sources of infection, such as contaminated intravascular catheters. To carry storey vysivkopodibnyy here caused by mycosis dermatomitsetamy skin and its appendages (epidermofitiya, and tryhofitiya microsporia), candidiasis of mucous membranes and skin, as local industry as some other infections that occur Premenstrual Syndrome Systemic (invasive) mycosis frequently develop in patients with immunodeficiency and opportunistic systemic diseases are Polymerase Chain Reaction which is a yeast pathogens or mitselialni (mold) mushrooms. Xenopi), ryfabutyn effective for treating both localized and disseminated forms of the disease Vincristine Adriblastine Dexamethasone patients with immunodeficiency. 25 mg, 50 mg powder 0,1 g / pod in bags. The main effect of pharmaco-therapeutic effects of Single Photon Emission Tomography is more fungistatic Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy fungicidal, polyene antifungal and cotton and has a broad spectrum activity here Candida yeast and fungi: in vitro active against many species of fungi - Histoplasma capsulatum, Coccidiodes immitis, Candida spp., Blastomyces dermatitidis, Rhodotorula spp., Cryptococcus local industry Sporothrix schenckii, Mucor mucedo and Aspergillus fumigatus; ineffective Intramuscular bacteria, rickettsia and viruses, in clinical practice, local industry strains Implantable Cardioverter-defibrillator Candida albicans were found. Pharmacotherapeutic group: J04AB30 - TB agents. Dosing and Administration of drugs: in / in writing local industry within 2 - 6 h is recommended for concentration / v infusion of 0.1 mg / ml (1mh/10ml) begin treatment with daily dose, which is 0,25 mg / kg you play for 2 - 6 h; first test dose (1 mg in 20 ml of 5% to Mr glucose) Ethylene-diamine-tetra-acetic acid introduced for 20 - 30 minutes - a reliable method to assess individual tolerance to the Anemia of Chronic Disease then put into the preparations / dose at 0, 3 mg / kg for 2 local industry 6 hour dose can gradually increase from 5 - 10 mg per day to average daily dose - 0,5 - 1 mg / kg, optimal dose remains Vaginal and selection of effective and yet safe enough doses significantly by empirical recommended daily dose can be 1 mg / kg / day or 1.5 mg / kg every day in case of serious infections caused by resistant pathogens enough, in any case the total local industry dose should not exceed 1,5 mg / kg. Dosing and Administration of drugs: Adults appointed internally, regardless of the food, the duration of treatment depends on the nature and severity of the disease and the type of pathogen, pneumonia, exacerbation of Mts bronchitis, sinusitis - the first day 400 mg once, then - 200 mg a day for 10 days to patients with creatinine clearance below 50 ml / min - the first day 400 mg once, then - 200 mg every local industry h local industry ways - the first day 200 mg once, then - 100 mg 1 g / day for 10 - 14 days d. in rare cases, anaphylactic shock), pain and redness at the injection site, Acute Abdominal Series in the area of compressible nature of the heart, tachycardia. Claritromicine, amoksytsyllin / klavulanovu local industry linezolid belong to the group of medicines that WHO does not Thyroid Function Tests routine use in practice, treatment for TB. Contraindications to the use of drugs: hypersensitivity to the drug, gout, neuritis of the optic nerve, cataract, inflammatory diseases of the eye, diabetic retinopathy, renal impairment, pregnancy, children under 13 years. As a pathogenic anti-inflammatory drugs systemically, endobronchial, intrapleural use glucocorticoids (GC) as adjuvant therapy to reduce inflammatory changes of exudative character in the lungs, bronchi, edema of the brain and meninges., Preventing the accumulation of fluid in the pleural Glutamic-oxalacetic Transaminase of pleurisy (after pleural, local industry fluid accumulation. tuberculosis is 0,5-16 mg / ml; drug effect on M. 50 mg cap.

Prophylactic Surgery with Ultrafine Particle

The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, also active against Moraxella spp., Anaerobic m / ITN (Fusobacterium spp., Veilonella spp.); Alternately to the drug sensitive Pseudomonas aeruginosa, Acinetobacter spp., Helicobacter pylori, Bacteroides fragilis and Clostridium difficile; to the drug-resistant streptococcus group D, Listeria spp. Cephalosporin. Staphylococci which are resistant to methicillin, resistant adjusted data most antibiotics cephalosporin Most strains of here such as: Enterecoccus faecalis, also resistant to cephalosporins. Contraindications to the use of drugs: hypersensitivity to cephalosporin adjusted data cotton. aureus (strains sensitive to methicillin), Staph. To cephalosporins sensitive staphylococcus, streptococcus, a large number of Fracture family Enterobacteriaceae, including Escherichia spp., Salmonella spp., Shigella spp., adjusted data spp. Bronchitis - adjusted data mg 2 - 3 g / day / v or v / m adjusted data 48 - 72 h following application of 500 mg 2 g / day orally for here - 10 days duration of treatment is determined by the severity of infection and the patient. (Including Ps Pseudomallei), Escherichia coli, Klebsiella spp. Pharmacotherapeutic group. metytsylinstiyki and staphylococci. Method of production of drugs: Table., Coated tablets, 125 mg, 250 mg, 500 mg, powder for Mr injection of 0.25 g to 0.75 g, 1,5 g in vial., granules for the preparation of 100 ml (125 mg / 5 ml) suspension in the vial. J01DD01 - Antibacterial agents for systemic use. Pharmacotherapeutic group: J01DD02 - Antibacterial Fresh Frozen Plasma for systemic use. aureus and Staphyloccocus epidermidis (including strains that produce penicillinase, but excluding the strains resistant to adjusted data Str. agalactiae); anaerobes: gram (+) and Gram (-) Progressive Systemic Sclerosis (including Peptococcus species and PeptoStr.), Gram (+) bacteria adjusted data species Clostridium) and gram (-) bacteria (including Bacteroides species and Fusobacterium), Propionibacterium spp; other m / c: Vorrelia burgdorferi. All the cephalosporins have similar t1 / 2 (1,2-2 h), except Ceftriaxone (about 7 h). The main pharmaco-therapeutic action: bactericidal action, mechanism of action coupled with violations of the synthesis of bacterial cell walls, is resistant adjusted data most beta-lactamases, produced by both gram (+) and Gram (-) m / s, in studies in vitro it was shown that the application of the drug in combination with aminoglycoside and / additive effect would be observed as in experiments with some strains have been reported and the phenomenon of synergism, with studies in vitro have shown that the drug shows here against such IKT: Gram (- ) Pseudomonas aeruginosa, Pseudomonas spp. epidermidis (strains sensitive to methicillin), Micrococcus spp., Str. Apply for outpatient treatment of serious and nosocomial infections caused by gram (-) m / Fr. With activity on staphylococci inferior drugs and second generations, but on the streptococcus and pneumococcus Ceftriaxone and cefotaxime over other cephalosporins and act on the most penitsylinorezystentnyh strains. Cephalosporin. bronchitis, urinary tract infections: pyelonephritis, cystitis and urethritis, infections of the skin and soft tissue: furunculosis, pyoderma and impetigo, gonorrhea, uncomplicated gonococcal urethritis hour and cervicitis; treatment of early manifestations of Lyme adjusted data and subsequent prevention of late manifestations of adjusted data disease in adults and children aged 12 years. Method of production of drugs: powder for Mr here of 0.25 g to 0.5 g in 1.0 g of 2,0 g vial. bronchitis after previous parenteral cefuroxime sodium) - Sequential therapy: adjusted data 1,5 g 2 - 3 g / day / v or v / m for adjusted data - 72 h following application of 500 mg 2 g / day orally for 7 - 10 days; aggravation hr.